Category

News Brief

UF Team Plays Major Role in Success of Newly Approved Duchenne Muscular Dystrophy Drug

Duchenne muscular dystrophy families, advocates and healthcare providers celebrated a milestone in March with the U.S. Food and Drug Administration’s approval of the first nonsteroidal drug for the treatment of Duchenne. The University of Florida's expertise in magnetic resonance imaging provided objective, measurable results in the drug's clinical trials.

The University of Florida’s Plans in Jacksonville: Where They Stand

Jacksonville is poised to become the home of two new University of Florida institutions that would play into UF President Ben Sasse’s vision of the university partnering with businesses to apply research to current and future challenges, putting students closer to prospective employers and spurring the regional and state economies.

UF Team Works to Create Most Resilient Sensor on Earth

A diverse team led by three ECE Florida faculty members is set to receive funding from the Defense Advanced Research Projects Agency (DARPA) to design and fabricate dynamic pressure sensors capable of performing at temperatures upwards of 800 °C (1472 °F), over a factor of 6X higher than any integrated pressure sensor currently in use. The $6.6M project, funded as part of the DARPA High Operational Temperature Sensors (HOTS) program, seeks to enable the creation of electronics and sensors integral to industrial, military, and space applications. The core team comprises Dr. Mark Sheplak (lead PI), Dr. Roozbeh Tabrizian, and Dr. Philip Feng.

Making Advances in Space Engineering

Humanity’s ambitions for space engineering are growing -- manned missions to Mars, permanent lunar bases, and ever-larger telescopes to peer into the cosmos. To fulfill those ambitions, the University of Florida has launched the Space Mission Institute, an interdisciplinary hub for space research.

Targeting RNA

Disney and his team at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida, have discovered more than 200 unique RNA-targeting compounds. His methods and discoveries have changed minds, igniting a global race to treat incurable diseases via their RNA.

Satlantis Appoints Aitor Moriñigo Muñoz as First CEO of U.S. Subsidiary, Satlantis LLC

Satlantis, a technology company specializing in high-resolution Earth observation payloads for microsatellites, is pleased to announce the appointment of Aitor Moriñigo Muñoz as the first Chief Executive Officer (CEO) of their American subsidiary, Satlantis LLC, a UF startup and resident client at UF Innovate | Accelerate. Morinigo Munoz brings industry experience and expertise to this pivotal role.